Physician profile

Eric Bihler

Critical Care Medicine (Internal Medicine) · Pittsburgh, PA

NPI 1336316793

$21,595.39

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$3,600.00
Food and Beverage$223.70

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Insmed, INC. $21,305.10 2019-2023 Arikayce
Astrazeneca Pharmaceuticals Lp $193.18 2019-2022
Mylan Specialty L.P. $35.13 2022
Vapotherm INC $18.81 2019
Horizon Therapeutics Plc $15.83 2020
Boehringer Ingelheim Pharmaceuticals, INC. $14.64 2021
Merck Sharp & Dohme LLC $12.70 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eric Bihler

$21,595.39

in general payments reported 2019-2025

Years
2019-2023
Top company
Insmed, INC.

https://glasscript.com/doctor/196207/eric-bihler

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.